Mission 03 · NAD+ / research guide

The number rose.
Then what?

NAD+ matters to cells. A higher blood reading still needs a health result beside it.

About 3 min · Study settings kept in view

A sunlit wooden path winding through golden dunes toward the sea
Supernova mission patch

The short version.

Human trials of oral NR and NMN raised blood NAD+. Some found specific functional changes. Lasting disease prevention and longer human life remain unproved.

The substance
NAD+ is a coenzyme
The trials
Oral NR & NMN
The catch
Blood isn't every tissue

Mission log / 01

First, NAD+ is not a peptide

NAD+ is a coenzyme: a helper molecule used by enzymes. It helps with energy-releasing reactions and is used in processes including DNA repair, as the review of NAD+ biology explains.

NR and NMN are precursors—materials the body can turn into NAD+. The human trials here gave those materials by mouth. A result for one precursor is not automatically a result for NAD+ itself, a different preparation, or an infusion.

Mission log / 02

A higher blood level is the clearest result

In an eight-week NR trial in healthy overweight adults, whole-blood NAD+ increased. There were no significant differences in adverse events from placebo over that short study.

That supports a narrow, useful conclusion about blood levels and short-term observations in that group. It does not show that the brain or muscle changed in the same way, or that people will avoid disease or live longer.

Mission log / 03

Some human outcomes did change

A 60-day NMN study in healthy middle-aged adults reported improvements in walking distance and quality-of-life scores as well as blood NAD+. It is worth noticing an outcome someone might feel, while keeping the short follow-up in view.

In a ten-week trial in prediabetic, postmenopausal women, NMN improved muscle insulin sensitivity: muscle responded better to the hormone that helps it take up glucose. Body composition and HbA1c, a longer-term blood-sugar measure, did not change.

One improvement can sit beside unchanged results. These participants also cannot stand in for everyone who feels tired or is getting older.

Mission log / 04

The replenishment idea still has gaps

The 2025 review of human precursor trials found limited efficacy and sparse tissue-specific data. Even the familiar claim that NAD+ falls with age rests on a limited number of consistent human studies.

The biology is a reason to ask better questions. It is not proof that raising a blood number slows aging. The useful next result would connect a defined preparation with a lasting health benefit in a defined group of people.

A blood test can show that something changed. The next question is whether life changed with it.

The Supernova takeaway
Next flight path Compare the experiments side by side